Meet James | Pradaxa® Patient Profiles | Boehringer Ingelheim
- 66 years old
- Enjoys swimming and travelling
around the world with his wife
- Recently diagnosed with nonvalvular atrial fibrillation
(NVAF) but is not yet on treatment
What will you and James
discuss when considering
What are the risks of
What happens if he is
With Pradaxa®, James can feel confident
Major bleeding risk among NOACs vs warfarin (n=61,678), as measured
in an independent, real-world, observational analysis1
Not a head-to-head study; this was a real-world, observational analysis comparing the effectiveness and safety of standard doses of Pradaxa®, rivaroxaban, and apixaban vs warfarin.
If James ever needs it, Praxbind® provides the reassurance of specific, immediate, and complete reversal of Pradaxa®
Dual indication—for life-threatening or uncontrolled bleeding and emergency surgery/urgent procedures2
Specific binding allows for immediate and complete reversal of Pradaxa® with no procoagulant effects2
Easy to use—1 ready-to-use dose for ALL Pradaxa® patients2
Widely available—8,300+ sites in 48 countries3
- 1. Larsen TB et al. BMJ. 2016;353:i3189.
- 2. Praxbind® (idarucizumab) Summary of Product Characteristics. 2018.
- 3. Data on file, Boehringer Ingelheim.